Cost-effectiveness analysis of nilotinib versus imatinib for the treatment of chronic phase philadelphia chromosome positive chronic myeloid leukaemia

Mildred, M., Ward, S., Squires, H. et al. (1 more author) (2012) Cost-effectiveness analysis of nilotinib versus imatinib for the treatment of chronic phase philadelphia chromosome positive chronic myeloid leukaemia. In: 17th Congress of EHA, 14-17 June 2012, Amsterdam, The Netherlands.

Abstract

Metadata

Authors/Creators:
  • Mildred, M.
  • Ward, S.
  • Squires, H.
  • Gray, E.
Keywords: Antineoplastic Agents; Clinical Trials; Cost-Benefit Analysis; Drug Costs; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Markov Chains; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quality-Adjusted Life Years; Survival Analysis
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Health and Related Research (Sheffield) > Health Economics and Decision Science
The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Health and Related Research (Sheffield)
Funding Information:
FunderGrant number
Novartis Pharmaceuticals UK LtdUNSPECIFIED
Depositing User: Mr Matthew Mildred
Date Deposited: 18 May 2012 10:03
Last Modified: 04 Jun 2014 18:55
Status: Published
Refereed: Yes

Download

Filename: Mildred_2012_EHA_poster.pdf

Share / Export